A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT02574078
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUG
- Bevacizumab — DRUG
- Pemetrexed — DRUG
- Best Supportive Care — OTHERPalliative radiation, palliative surgery and/or other best supportive care treatments
- nab-Paclitaxel — DRUG
- Paclitaxel — DRUG
- Docetaxel — DRUG
- Gemcitabine — DRUG
- Erlotinib — DRUG
- Crizotinib — DRUG
- Carboplatin — DRUG
Study Details
The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Key Dates
- Start date
- Nov 23, 2015
- Status verified
- Apr 2021
- Primary completion
- Apr 15, 2020
- Completion
- Apr 15, 2020
Study Design
- Enrollment
- 341 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group A NivolumabOpdivo specified dose on specified days
- Experimental: Group A Nivolumab + SOC maintenance therapyOpdivo/Bevacizumab specified dose on specified days Opdivo/Pemetrexed specified dose on specified days
- Active Comparator: Group A SOC maintenance therapyBevacizumab specified dose on specified days Pemetrexed specified dose on specified days
- Experimental: Group B NivolumabOpdivo specified dose on specified days
- Other: Group B Best supportive careTherapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
- Active Comparator: Group C Investigator's choice chemotherapyCarboplatin/nab-paclitaxel specified dose on specified days Carboplatin/paclitaxel specified dose on specified days Carboplatin/pemetrexed specified dose on specified days Carboplatin/docetaxel specified dose on specified days Carboplatin/gemcitabine specified dose on specified days Paclitaxel specified dose on specified days Docetaxel specified dose on specified days Gemcitabine specified dose on specified days Pemetrexed specified dose on specified days
- Experimental: Group C NivolumbOpdivo specified dose on specified days
- Active Comparator: Group D ErlotinibErlotinib specified dose on specified days
- Experimental: Group D Nivolumab + ErlotinibOpdivo/Erlotnib specified dose on specified days
- Experimental: Group E Nivolumab + CrizotinibOpdivo/Crizotinib specified dose on specified days
Primary Outcome Measure
Progression-Free Survival (PFS), Groups A-D Only [ Time Frame: up to approximately 48 months ]
Locations (133)
Find similar trials in Birmingham, AL
By condition
By specialty
By research site
Related Studies
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California